Jangee (Drospirenone, Ethinylestradiol | Lactose)

Jangee, a combined oral contraceptive, is used in the hormonal contraception pathway to prevent pregnancy and to manage menstrual cycle disorders.

• Prevention of pregnancy: provides reliable contraceptive protection by inhibiting ovulation.
• Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces cycle irregularities.
• Management of dysmenorrhea: may lessen menstrual pain and associated premenstrual symptoms.

• Jangee combines drospirenone, a synthetic progestogen with anti‑mineralocorticoid activity, and ethinylestradiol, a synthetic estrogen. The estrogen suppresses follicle‑stimulating hormone, while drospirenone blocks the luteinizing hormone surge, together inhibiting ovulation. The progestogenic effect also thickens cervical mucus and induces endometrial changes that reduce the likelihood of fertilisation and implantation.

Oral administration of Jangee may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or mood swings.
• Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: significant increase in blood pressure.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Jangee, clinicians should consider several precautionary measures to ensure safe use.

• Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease.
• Smoking: do not prescribe to smokers over 35 years of age due to increased cardiovascular risk.
• Cardiovascular risk: assess blood pressure and lipid profile before initiation.
• Pregnancy testing: confirm non‑pregnant status prior to starting therapy.
• Breastfeeding: evaluate risk‑benefit, as estrogen may affect milk production.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Jangee can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness.
• Rifampicin or other strong CYP3A4 inducers: can markedly decrease hormone levels.
• St. John’s wort: potent inducer that may lead to contraceptive failure.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk.
• Certain antibiotics (e.g., clarithromycin): can modestly affect hormone metabolism.
• Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood‑related side effects.
• Herbal supplements containing phytoestrogens: monitor for additive estrogenic effects.